Bayer has agreed to fully acquire Perfuse Therapeutics, a biopharmaceutical company pioneering transformational research into the treatment of ischemia-induced ocular diseases. Under the terms of the agreement, the transaction carries a total potential value of up to $2.45 billion, comprising a $300 million upfront payment and additional development, regulatory, and commercial milestone payments based on success criteria. Perfuse Therapeutics’ Investigational Lead Program With this acqu...